Better Buy: Ocugen vs. Pfizer
Ocugen: Potential for major gainsAdria Cimino
$Ocugen (OCGN.US)$ : Ocugen surged more than 700% in a matter of weeks earlier this year on optimism about potential coronavirus vaccine sales. The biotech company partnered with Bharat Biotech to co-commercialize that company's vaccine -- Covaxin -- in the U.S. The deal later expanded to include Canada. But Ocugen has struggled to actually bring Covaxin to market. As a result, shares have dropped 68% from their peak back in February.
Pfizer: Something to attract nearly every investorKeith Speights
$Pfizer (PFE.US)$ : If you're an income-seeking investor, Pfizer is a no-brainer choice over Ocugen. The big drugmaker's dividend currently yields 2.7%. It's a pretty safe bet that Pfizer will increase its dividends for years to come. Ocugen, of course, doesn't make enough money to pay a dividend.
Ocugen or Pfizer?Your choice may depend on your investing style. An investor looking for a chance at steep gains fast may go for Ocugen. But as Keith says, the risk is that such a stock also may suffer big losses. Overall, Pfizer represents an opportunity to grow your investment over time -- and expose yourself to a lot less risk. In general, that's always a better recipe for long-term investing success.
Part of the content is taken from The Motley Fool.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Evelynne : $Pfizer (PFE.US)$ Pfizer Announces It's VYNDAQEL/VYNDAMAX Reduced The Risk Of All-Cause Mortality By 41% Among Patients With Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate.